BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31582176)

  • 1. Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.
    Chanal E; Bouleftour W; Guillot A; Rowinski E; Bernichon E; Tremeau L; Lardon R; Lacroix B; Lorin S; Delorme G; Perraud Y; Armand C; Levigne F; Vallard A; Langrand-Escure J; Fournel P; Benoite M; Vassal C
    Bull Cancer; 2019 Dec; 106(12):1086-1093. PubMed ID: 31582176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.
    Avulova S; Allen C; Morgans A; Moses KA
    Urol Oncol; 2018 Jul; 36(7):342.e1-342.e6. PubMed ID: 29754945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of stage I testicular germ cell tumours.
    Chovanec M; Hanna N; Cary KC; Einhorn L; Albany C
    Nat Rev Urol; 2016 Nov; 13(11):663-673. PubMed ID: 27618772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
    Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
    Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of localized germ-cell tumours of the testis].
    Loriot Y; Fizazi K
    Rev Prat; 2007 Feb; 57(4):379-84. PubMed ID: 17455739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
    Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
    Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT).
    Ann Oncol; 2001 Sep; 12(9):1215-6. PubMed ID: 11697829
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
    Heidenreich A; Pfister D
    Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy].
    Mottet N; Rousmans S; Culine S
    Bull Cancer; 2008 Feb; 95(2):205-34. PubMed ID: 18330045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours.
    Pedraza AM; Stephenson AJ
    Curr Opin Urol; 2018 Sep; 28(5):448-453. PubMed ID: 29979237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of stage I nonseminomatous testicular germ cell tumors.
    Pectasides D; Farmakis D; Pectasides M
    Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.